ITI-214

DRUG3 trials

Sponsors

Intra-Cellular Therapies, Inc.

Conditions

Healthy VolunteersHeart Failure, SystolicParkinson Disease

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

CompletedNCT03257046

Intra-Cellular Therapies, Inc.Parkinson Disease

Start: 2017-09-28End: 2018-09-28Updated: 2018-12-20

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

CompletedNCT03387215

Intra-Cellular Therapies, Inc.Heart Failure, Systolic

Start: 2018-07-10End: 2020-03-16Updated: 2020-12-24

Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement

CompletedNCT03489772

Intra-Cellular Therapies, Inc.Healthy Volunteers

Start: 2018-07-10End: 2019-08-05Updated: 2019-11-06

Related Papers

Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial.

2022-04-296 citations

Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure

Circulation Heart Failure2021-08-3126 citations